Moreover, TGFβ inhibition has been shown to reduce myofibroblast features, while increasing immunomodulatories properties in murine carcinomas, thereby providing the rationale of combining TGFβ and PD-1/PD-L1 in clinical settings [155]. The gene discussed is TGFB1; the disease is carcinoma.